According to the Zhitong Finance App, Fosun Pharmaceutical (02196.HK) announced its 2026 interim results, with operating income of about 20.442 billion yuan, up 4.75% year on year; net profit attributable to shareholders of listed companies was about 1,721 billion yuan, up 1.15% year on year; after deducting non-net profit of about 1,144 billion yuan, up 19.09% year on year; basic earnings per share were 0.65 yuan. Net cash flow from operating activities was approximately $2,424 million, up 13.59% year over year.

According to the Zhitong Finance App, Fosun Pharmaceutical (02196.HK) announced its 2026 interim results, with operating income of about 20.442 billion yuan, up 4.75% year on year; net profit attributable to shareholders of listed companies was about 1,721 billion yuan, up 1.15% year on year; after deducting non-net profit of about 1,144 billion yuan, up 19.09% year on year; basic earnings per share were 0.65 yuan. Net cash flow from operating activities was approximately $2,424 million, up 13.59% year over year.